Production & Manufacturing

Achieving optimal efficiency in pharmaceutical transport requires an uncompromising focus on transparency. Real-time visibility provides the necessary tools for connected tracking and thermal monitoring, ensuring that drug distribution systems remain secure and effective. By providing continuous oversight of the supply chain, these technologies allow for immediate intervention and data-driven optimization, protecting the integrity of life-saving medications throughout their entire journey.

Holista Colltech Limited has entered into a binding joint venture agreement with Swang Chai Chuan Limited to establish and operate an ovine nano-collagen manufacturing facility in Collie, Western Australia. The project will be carried out through Ovicoll Pty Ltd,...

AddParts, a UK-based technology company focused on improving operational continuity in pharmaceutical production environments, has secured a six-figure pre-seed investment from SFC Capital to support the expansion of its virtual storeroom technology. Announced on 29 April 2026 in Sheffield,...

A new initiative from Made Smarter is aiming to simplify how manufacturers approach artificial intelligence, with a focus on practical deployment rather than theoretical potential. The organisation has introduced a downloadable guide titled AI Adoption in Manufacturing: A Practical...

Building a compelling Series B case in biopharma goes well beyond efficacy data and market size projections. Sophisticated investors are increasingly focused on CMC risk, licensing obligations, and the defensibility of your manufacturing timeline. This article breaks down what the financial model behind a strong Series B actually looks like and what quietly kills deals that should have worked.

Ask any experienced biopharma program manager what derails an IND filing most often, and the answer is rarely surprising: it is CMC. Not insufficient efficacy data, not toxicology surprises CMC. This article examines why Chemistry, Manufacturing, and Controls continues to be the most underestimated risk in early drug development, and what program leaders can do about it.

Choosing a gene expression system is one of the earliest and most consequential manufacturing decisions a biotech founder will make yet it is often made without fully understanding what is at stake. This article breaks down the key expression platforms used in biologic drug development, what differentiates them technically and commercially, and why the choice you make now will follow your program all the way to the clinic and beyond.